Proteomics discovery of chemoresistant biomarkers for ovarian cancer therapy

被引：8
作者：
Deng, Junli [1 ,2 ,3 ,4 ]
Wang, Li [3 ,4 ]
Ni, Jie [1 ,2 ]
Beretov, Julia [1 ,2 ]
Wasinger, Valerie [5 ,6 ]
Wu, Duojia [1 ,2 ]
Duan, Wei [7 ]
Graham, Peter [1 ,2 ]
Li, Yong [1 ,2 ]
机构：
[1] St George Hosp, Canc Care Ctr, Kogarah, NSW, Australia
[2] Univ New South Wales UNSW, St George & Sutherland Clin Sch, Kensington, NSW, Australia
[3] Henan Canc Hosp, Dept Gynecol Oncol, Zhengzhou, Peoples R China
[4] Zhengzhou Univ, Zhengzhou, Peoples R China
[5] Univ New South Wales UNSW, Mark Wainwright Analyt Ctr, Bioanalyt Mass Spectrometry Facil, Kensington, NSW, Australia
[6] Univ New South Wales UNSW, Sch Med Sci, Kensington, NSW, Australia
[7] Deakin Univ, Sch Med, Waurn Ponds, Australia
来源：
EXPERT REVIEW OF PROTEOMICS | 2016年 / 13卷 / 10期
关键词：
Mass spectrometry; ovarian cancer; proteomics; chemoresistance; biomarker; TANDEM MASS TAGS; QUANTITATIVE PROTEOMICS; PACLITAXEL-RESISTANCE; CISPLATIN RESISTANCE; MULTIDRUG-RESISTANCE; PROTEIN QUANTITATION; IDENTIFICATION; CELLS; QUANTIFICATION; SUBTYPES;
D O I：
10.1080/14789450.2016.1233065
中图分类号：
Q5 [生物化学];
学科分类号：
071010 ; 081704 ;
摘要：
Introduction: Chemoresistance is a major challenge to current ovarian cancer chemotherapy. It is important to identify biomarkers to distinguish chemosensitive and chemoresistant patients.Areas covered: We review the medical literature, discuss MS-based technologies with respect to chemoresistant ovarian cancer and summarize the promising chemoresistant biomarkers identified. In addition, the challenges and future perspectives of biomarker discovery research are explored. With the employment of mass spectrometry-based (MS-based) proteomics, biomarker discovery of ovarian cancer has made great progress in the last decade. Many potential biomarkers were identified by MS-based proteomics technologies, some of which have been validated for further extensive studies in clinical settings.Expert commentary: The discovery of chemoresistant biomarkers is a newly developing area and may provide a clue for predicting chemotherapeutic response and discover therapeutic targets for paving the way of personalized medicine. Multiple complementary MS-based proteomics approaches hold promise for finding novel therapeutic targets in ovarian cancer treatment.
引用
收藏
页码：905 / 915
页数：11
相关论文
共 76 条
[21]   Proteomics of ovarian cancer: functional insights and clinical applications [J].
Elzek, Mohamed A. ;
Rodland, Karin D. .
CANCER AND METASTASIS REVIEWS, 2015, 34 (01) :83-96
[22]   Biological and Biomedical Applications of Two-Dimensional Vibrational Spectroscopy: Proteomics, Imaging, and Structural Analysis [J].
Fournier, Frederic ;
Guo, Rui ;
Gardner, Elizabeth M. ;
Donaldson, Paul M. ;
Loeffeld, Christian ;
Gould, Ian R. ;
Willison, Keith R. ;
Klug, David R. .
ACCOUNTS OF CHEMICAL RESEARCH, 2009, 42 (09) :1322-1331
[23]   Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development [J].
Frantzi, Maria ;
Bhat, Akshay ;
Latosinska, Agnieszka .
CLINICAL AND TRANSLATIONAL MEDICINE, 2014, 3
[24]   Targeted Data Extraction of the MS/MS Spectra Generated by Data-independent Acquisition: A New Concept for Consistent and Accurate Proteome Analysis [J].
Gillet, Ludovic C. ;
Navarro, Pedro ;
Tate, Stephen ;
Roest, Hannes ;
Selevsek, Nathalie ;
Reiter, Lukas ;
Bonner, Ron ;
Aebersold, Ruedi .
MOLECULAR & CELLULAR PROTEOMICS, 2012, 11 (06)
[25]   Proteomic analysis of cisplatin resistance in human ovarian cancer using 2-DE method [J].
Gong, Fengming ;
Peng, Xingchen ;
Zeng, Zhi ;
Yu, Ming ;
Zhao, Yuwei ;
Tong, Aiping .
MOLECULAR AND CELLULAR BIOCHEMISTRY, 2011, 348 (1-2) :141-147
[26]  
Gundry R. L., 2009, CURR PROTOC MOL BIOL, DOI DOI 10.25.1-10.25.23
[27]   Proteomic developments in the analysis of formalin-fixed tissue [J].
Gustafsson, Ove J. R. ;
Arentz, Georgia ;
Hoffmann, Peter .
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS, 2015, 1854 (06) :559-580
[28]   Evaluating the effects of preanalytical variables on the stability of the human plasma proteome [J].
Hassis, Maria E. ;
Niles, Richard K. ;
Braten, Miles N. ;
Albertolle, Matthew E. ;
Witkowska, H. Ewa ;
Hubel, Carl A. ;
Fisher, Susan J. ;
Williams, Katherine E. .
ANALYTICAL BIOCHEMISTRY, 2015, 478 :14-22
[29]   Defining, Comparing, and Improving iTRAQ Quantification in Mass Spectrometry Proteomics Data [J].
Hultin-Rosenberg, Lina ;
Forshed, Jenny ;
Branca, Rui M. M. ;
Lehtio, Janne ;
Johansson, Henrik J. .
MOLECULAR & CELLULAR PROTEOMICS, 2013, 12 (07) :2021-2031
[30]   A Serum Protein Profile Predictive of the Resistance to Neoadjuvant Chemotherapy in Advanced Breast Cancers [J].
Hyung, Seok-Won ;
Lee, Min Young ;
Yu, Jong-Han ;
Shin, Byunghee ;
Jung, Hee-Jung ;
Park, Jong-Moon ;
Han, Wonshik ;
Lee, Kyung-Min ;
Moon, Hyeong-Gon ;
Zhang, Hui ;
Aebersold, Ruedi ;
Hwang, Daehee ;
Lee, Sang-Won ;
Yu, Myeong-Hee ;
Noh, Dong-Young .
MOLECULAR & CELLULAR PROTEOMICS, 2011, 10 (10)
12345678